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Abstract
Background: NPM1 gene at chromosome 5q35 is involved in recurrent translocations in leukemia and lymphoma. It also
undergoes mutations in 60% of adult acute myeloid leukemia (AML) cases with normal karyotype. The incidence and
significance of NPM1 deletion in human leukemia have not been elucidated.
Methodology and Principal Findings: Bone marrow samples from 145 patients with myelodysplastic syndromes (MDS) and
AML were included in this study. Cytogenetically 43 cases had isolated 5q-, 84 cases had 5q- plus other changes and 18
cases had complex karyotype without 5q deletion. FISH and direct sequencing investigated the NPM1 gene. NPM1 deletion
was an uncommon event in the ‘‘5q- syndrome’’ but occurred in over 40% of cases with high risk MDS/AML with complex
karyotypes and 5q loss. It originated from large 5q chromosome deletions. Simultaneous exon 12 mutations were never
found. NPM1 gene status was related to the pattern of complex cytogenetic aberrations. NPM1 haploinsufficiency was
significantly associated with monosomies (p,0.001) and gross chromosomal rearrangements, i.e., markers, rings, and
double minutes (p,0.001), while NPM1 disomy was associated with structural changes (p=0.013). Interestingly, in complex
karyotypes with 5q- TP53 deletion and/or mutations are not specifically associated with NPM1 deletion.
Conclusions and Significance: NPM1/5q35 deletion is a consistent event in MDS/AML with a 5q-/-5 in complex karyotypes.
NPM1 deletion and NPM1 exon 12 mutations appear to be mutually exclusive and are associated with two distinct
cytogenetic subsets of MDS and AML.
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Introduction
In humans, nucleophosmin (NPM1) is implicated in the genesis of
different cancers [1]. We previously found NPM1 exon 12 somatic
mutations in approximately 60% of adult acute myeloid leukemia
(AML) and normal karyotype [2]. NPM1 fusion proteins are
also specifically involved: t(5;17)(q35;q21)/NPM1-RARA causes acute
promyelocytic leukemia; t(2;5)(p23;q35)/NPM1-ALK underlies ana-
plastic large cell lymphoma; t(3;5)(q26;q35)/NPM1-MLF1 is associated
with myelodysplastic syndromes (MDS) and AML with trilineage
dysplasia and poor prognosis (http://AtlasGeneticsOncology.org). In
the last cytogenetic subgroup of MDS/AML a cryptic loss
of NPM1 gene may occur at the 5q35 breakpoint of the
translocation [3]. Despite of this sporadic observation the role
of NPM1 deletion in hematological malignancies remains to be
elucidated. In human leukemia an interstitial isolated deletion
at chromosome 5q identifies a myelodysplastic syndrome with
a benign clinical course (the ‘‘5q- syndrome’’) [4]. Moreover a
partial or complete 5q loss (5q-/-5) may occur as part of a
complex karyotype in high risk MDS/AML, including cases
arising after radio- and/or chemo-therapy [5]. Chromosomes
5q- are heterogeneous in size as deleted segments vary in
extension and have different centromeric and telomeric
breakpoints [6,7]. Experimental evidences indicate that the
5q- syndrome originates from haploinsufficiency of more than
one critical pathogenetic gene included in the hemizygous
chromosome deletion [8–12]. Thus identification of genes
that go lost in different 5q- chromosomes of MDS and AML is
very important to understand the pathophysiology of the
associated malignant disorders. Focusing on NPM1 gene we
investigated a large series of MDS and AML with and without
a 5q deletion.
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Patient inclusion criteria
AML or MDS and one of the following abnormal karyotypes,
according to the ISCN [13]: isolated 5q-; 5q-/-5 plus one or more
additional changes (non-isolated); complex karyotypes without 5q-/-5.
145 patients (60 males; 85 females; age range 9–94 years; 71 with MDS
and 74 with AML) were recruited from the Hematological Institutions,
University of Perugia, Italy, Sant Pau Hospital, Barcelona, Spain, and
the Demokritos Cancer Centre, Athens, Greece.
FISH
Protocols have already been described [14]. Commercial FISH
probes were provided by Abbott/Vysis (Downers Grove, IL, USA):
LSI EGR1/D5S721, D5S23 dual color probe; LSI CSF1R (5q33–
q34) spectrum orange/D5S721, D5S23 spectrum green; LSI c-MYC
dual color break apart rearrangement probe; LSI 13 (RB1) 13q14
spectrum orange probe. Caltech DNA clones CTC-286C20 (FGFR4/
5q35.2), CTC-549A4 (NSD1/5q35.3), CTD-2131H15 (39CTNNA1/
5q31), CTD-2324F6 (59CTNNA1/5q31), CTD-2342K5 (BRCA2/
13q12), and CTD-3199J23 (BRCA1/17q21) were purchased from
Invitrogen (Carlsbad, CA, USA). Other DNA clones were selected
from the RPCI libraries (http://www.ncbi.nlm.gov/project/mapview,
Build 37.1), provided by Mariano Rocchi, Department of Genetics and
Microbiology, University of Bari, Italy and grown, labelled, and
validated at the Cytogenetics and Molecular Genetics Laboratory,
HematologyDepartment,Universityof Perugia,Italy.Clonesmapping
at 5q11.2–5q14.1 listed from centromere to telomere: RP11-266N13,
RP11-489L13, RP11-298P6, RP11-79C20, RP11-170N5, RP11-
195G20, RP11-633M1, RP11-195E2, RP11-771B3, RP11-79P5,
RP5-910M8, RP11-229C3, RP11-469J18, RP11-996M9, RP11-
168A11, RP11-80K5, RP11-1089B2, and RP11-885P10. Gene-
specific RPCI clones: RP11-89G4 (IRF1/5q31), RP11-946D14
(RPS14/5q33), RP11-204L7 (39SPARC/5q33), RP11-642K17
(59SPARC/5q33), RP11-117L6 (NPM1/5q35.1), RP1-240G13 (5qter
subtelomeric probe), RP11-480O8 (BUB1A/2q14), RP11-383G6
(39ATR/3q23), RP11-427D1 (59ATR/3q23), RP11-669K4 (FBW7/
4q31), RP11-149I2 (CDKN2A/B/9p21), RP11-380G5 (PTEN/10q23),
RP11-241D13 (ATM/11q22), RP11-880O16 (CHEK1/11q24), RP11-
1137N1 (MDM2/12q15), RP11-248I17 (BUB1B/15q15), RP11-
436C9 (39CHEK2/22q12), RP11-444G7 (59CHEK2/22q12).
NPM1 and TP53 Mutational Analysis
Exon 12 NPM1 mutations were studied by direct sequencing of
PCR products from genomic DNA using the following primers:
NPM1_ex12for 59-ATGTCTATGAAGTGTTGTGGTTCC-39and
NPM1_ex12rev 59- CAGGCATTTTGGACAACACA-39. TP53
gene (NC_000017.10, 7590863.7571720) mutations on exons 2-12
(Table 1) were studied using PCR-based denaturing HPLC using a
WAVE-MD
TM System (Transgenomic, Omaha, NE) equipped with a
DNASep Cartridge. PCR assays were performed in a volume of 25 ml,
containing 100 ng of genomic DNA, 6 pmol of forward and reverse
primer, 200 mM dNTPs, 0.3 U of AmpliTaq Gold (Life Technologies
Corp.,Carlsbad,CA, USA). Gradient elution and melting temperature
conditions were established by Wave-Maker Navigator version 1.7
software (Transgenomic). Bidirectional sequencing was performed on
samples with abnormal chromatographs using ABI prism 3130 (Life
Technologies). Missense and frameshift mutations were detected using
Finch TV version 1.4.0 and described according to CCDS 11118.1
(NM_0000546.4).
NPM1 expression by Real Time Quantitative PCR
RT-qPCR was performed on cryopreserved bone marrow RNA
samples from 9 patients with NPM1+/- and 5q-, 10 patients with
NPM1+/+ and 5q-, 5 patients with NPM1+/+ without 5q- and 11
healthy controls. Total RNA was extracted using Trizol (Invitro-
gen) according to the manufacturer’s protocol with minor
modifications. Two micrograms of total RNA were treated with
4 Units of Dnase I (Deoxyribonuclease I Amplification Grade,
Sigma) in a total volume of 11 ml. One microgram of treated RNA
was reverse transcribed to single strand cDNA according to the
EAC protocol [15] and 1 mg was used in a control reaction (-RT)
using the same procedure without the M-MLV reverse transcrip-
tase enzyme (Perkin Elmer Applied Biosystems, Foster City, USA).
The RT-qPCR mixture reaction contained 12.5 ml Taq Man
Universal PCR Master Mix (Life Technologies), 300 nM primers,
200 nM probe and 5 ml cDNA (1/10 of RT product), in a total
volume of 25 ml. Amplification conditions were: 2 minutes at
50uC, 10 minutes at 95uC followed by 40 cycles at 95uC for 15
seconds and at 60uC for 1 minute [16]. RT-qPCR reactions and
fluorescence measurements were performed on an ABI PRISM
7700 Sequence Detection System (Life Technologies). Gene
expression levels of NPM1 and ABL1 were detected using specific
assays on Demand (Life Technologies) following the manufactur-
er’s instructions: ID: Hs02339479_g1 (exon 4–5) for NPM1 and
Table 1. Primers used to amplify TP53 coding exons
(NC_000017.10).
TP53 Exon Primer Sequence
2 P53_ex2F
P53_ex2TGF
P53_ex2R
59-TTTTCCTCTTGCAGCAGCCA-39
59-CCAGGTGACCCAGGGTTGGAAG-39
59-CAAGAGCAGAAAGTCAGTCC-39
3 P53_ex3F
P53_ex3R
59-AGACCTGTGGGAAGCGAAAA-39
59-GGGACAGCATCAAATCATCC-39
2–3 P53_ex2-3F
P53_ex2-3R
59-TGCCTTCCGGGTCACTGCC-39
59-AGCCCTCCAGGTCCCCAGCC-39
4 P53_ex4F
P53_ex4AF
P53_ex4R
P53_ex4AR
59-ATCTACAGTCCCCCTTGCCG-39
59-ACCTGGTCCTCTGACTGCTC-39
59-GCAACTGACCGTGCAAGTCA-39
59-GCCAAAGGGTGAAGAGGAAT-39
5 P53_ex5F
P53_ex5AF
P53_ex5R
P53_ex5AR
59-GCTGCCGTGTTCCAGTTG-39
59-GCTTTATCTGTTCACTTGTGCC-39
59-ACCAGCCCTGTCGTCTCTC-39
59-AGCCCTGTCGTCTCTCCAG-39
6 P53_ex6F
P53_ex6R
59-CCAGGCCTCTGATTCCTCAC-39
59-GCCCCCCTACTGCTCACC-39
7 P53_ex7F
P53_ex7R
P53_ex7AR
59-GCCACAGGTCTCCCCAAG-39
59-TGTGCAGGGTGGCAAGTG-39
59-TGCAGGGTGGCAAGTGGCTC-39
8 P53_ex8F
P53_ex8R
59-TGCCTCTTGCTTCTCTTTTCC-39
59-GGCATAACTGCACCCTTGG-39
9 P53_ex9F
P53_ex9R
59-GCGGTGGAGGAGACCAAG-39
59-GCTACAACCAGGAGCCATTG-39
10 P53_ex10F
P53_ex10R
59-GGCAGTGATGCCTCAAAGAC-39
59-CTAGGCTAAGCTATGATGTTCC-39
11 P53_ex11F
P53_ex11AF
P53_ex11DF
P53_ex11R
P53_ex11AR
P53_ex11BR
59-CCCCCTCCTCTGTTGCTGC-39
59-TACTTCTCCCCCTCCTCTG-39
59-GAACCATCTTTTAACTCAGGTAC-39
59-GGCAGGGGAGTAGGGCCAG-39
59-GAAGGCAGGATGAGAATGGA-39
59-AGCTGCCTTTGACCATGAAG-39
12 P53_ex12F
P53_ex12AF
P53_ex12BF
P53_ex12R
P53_ex12AR
59-CACTCATGTGATGTCATCTCTC-39
59-CTCACTCATGTGATGTCATCT-39
59-CTCTGAGGTGCTCAGTAAAC-39
59-GCTGTCAGTGGGGAACAAGA-39
59-GCAAGCAAGGGTTCAAAGAC-39
doi:10.1371/journal.pone.0012855.t001
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were performed in quadruplicate for NPM1 and in duplicate for
ABL1. NPM1 transcript levels were quantified relative to
endogenous ABL1 and expressed as 2
2DDCt [17]. Universal
Human Reference RNA (Stratagene, La Jolla, CA, USA) was
used as calibrator in all experiments. A threshold value of 0.1 was
used throughout the study.
Statistical analysis
Inter-group differences were analyzed by non parametric tests
using first analysis of variance (ANOVA) with the Kruskal-Wallis
test to compare three groups and the Mann-Whitney U test to
compare two. If significant, multiple comparisons were carried out
using the Mann-Whitney U test with the Bonferroni correction
(i.e. 0.05/numbers of comparisons). The multivariable Poisson
regression model analyzed the adjusted effect of NPM1 and TP53
on gross chromosomal changes and monosomies.
Contingency tables studied associations among categorical
variables which were analyzed by Fisher’s Exact test for 2X2
tables or the chi-square test. Unless otherwise indicated,
significance was set at ,0.05. SPSS version 17.0 software
(Chicago, IL) was used for statistical analysis.
Ethics statement
This study was carried out solely on encoded archival samples
that were originally taken for diagnostic purposes. The residual of
these samples was used after all diagnostic procedures had been
completed. Our specific study was approved by the Institutional
Review Board of the Hematology Department of the University of
Perugia (IRB 00003450) which guidelines allow the use of
anonymous residual diagnostic samples for research purposes.
Written informed consent was obtained. The ‘‘Demokritos’’
Cancer Research Centre Ethics Committee (Athens, Greece)
allows the use of anonymous or encoded residual diagnostic
samples for research purposes, unless the patient expresses its
refusal to participate in research studies. The authors declare that
all samples used in this study were encoded anonymously and that
none of the patients had explicitly refused to participate in
research.
Results and Discussion
One hundred forty five patients with MDS/AML (60 males and
85 females; median age=68 years, range 9–94) were included in
the study (Table S1).
The mono-allelic NPM1 deletion was a very infrequent lesion in
the ‘‘5q- syndrome’’ because it was not detected in 42/43 cases. It
identified two molecular sub-groups, here named NPM1+/2 and
NPM1+/+, since it was present in 38/84 (45%) cases with complex
karyotypes and 5q-. Interestingly Lessard et al. [18] demonstrated
loss of the 5q35 chromosome band in 30% of de novo and therapy
related AML. NPM1 loss may have occurred as an early step in
MDS/AML as it remained stably mono-allelic in 4 NPM1+/2
patients and did not develop in 6 NPM1+/+ over a median of 9
months follow-up (range: 2–156 months) (Table 2).
The NPM1 loss was not cryptic since it was absent in 18 patients
with complex karyotypes without 5q- (Table S1). Chromosome
5q breakpoints were distributed over a wide chromosomal area
within genomic regions which extended beyond the isolated 5q
deletion breakpoints. In NPM1+/2 patients telomeric breakpoints
clustered between NPM1 and FGFR4 (approximately 5.7 mega-
bases) in 4/16 cases and included subtelomeric sequences in 12
(75%) (Figure 1A,B,C, and Table S1). Centromeric breakpoints
involved chromosome bands from q11.2 to q14.1 in more than
50% and were proximal to RP11-80K5 (Figure 1A,B,C, and
Table S1). Notably in cases with isolated 5q deletions centromeric
breakpoints always fell distally to RP11-80K5 (Figure 1A and
Table S1).
Table 2. FISH: NPM1 status over time (median 9 months; range 2–156) in 10 adult patients with MDS/AML.
No. Diagnosis Karyotype
Follow-up
(months)/Disease status Karyotype/NPM1
Non-isolated 5q- NPM1 +/+
45 RA 47,XX,del(5q),+21 +156/AML 46,idem,-7,t(12;22(p13;q11))/U
48 RAEB 46,XX,add(11)(q),del(5q)/46,XX +24/RAEB U/U
57 AML 46,XX,del(5q),t(2;3)(p21;q26) +4/AML 45,idem,27/U
72 AML 45–46,
XX,t(3;11)(p21;q23),
del(5)(q13q31),27,+8,del(12)(p13),add(16)(p13),
add(17)(q),218,+mar/46,XX
+13/2
nd relapse U/U
73 RAEB 46,XX,del(5)(q13q33),del(7)(q22q32),del(7)(q22q32),
der(20)/46,idem,add(7)(q36)
+13/MDS-U U/U
76 AML 41–49,XY,del(2p),
der(3)(p21),25,del(8)(q22),der(13;15)
(q10;q10),217,218,+126 mar/46,XY
+5/2
nd relapse U/U
Non-isolated 5q- NPM1 +/2
93 AML 42–44,XX,25,add(6)(p21),+8,1–3mar +9/1
st relapse n.d./U
110 AML 44,XY,22,23,25,27,213,217,+mar1,+mar2,+mar3/46,XY +9/1
st relapse n.d./U
121 RAEB 40–48,XY,t(1;3)(p32;p21),25,27,213,218,220,222,
+126 mar/46,XY
+2/RAEB n.d./U
122 AML 40243,XY,add(1)(q),24,del(5)(q13q33),27,29,212,
217,220,+2-6mar
+9/resistant n.d./U
Patient no. (see Supplementary Table 1); AML, acute myeloid leukemia; RAEB, refractory anemia with excess of blasts; RA, refractory anemia; NPM1+/+ no monoallelic
NPM1 deletion; NPM1+/2 monoallelic NPM1 deletion; U, unchanged; n.d., not done.
doi:10.1371/journal.pone.0012855.t002
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monoallelic NPM1 deletion and heterozygous mutation can not
occur at the same time (Figure 1D and Table S1). Furthermore,
the NPM1 deletion corresponded to reduced NPM1 expression in
MDS/AML cells which was significantly lower in NPM1+/2 cases
than in the NPM1+/+ (P,0.001) and normal controls (P,0.001)
(Figure 2). Notably, NPM1 is a multifunctional protein which
regulates ribosome biogenesis, TP53 protein activity and stability,
ARF protein stability and localization, and DNA integrity
[1,19,20]. In keeping with evidence from murine models [21], in
which NPM1 loss induced morphological signs of MDS, favored
c-MYC lymphomagenesis and underlay chromosomal instability,
chromosome rearrangements constituting complex karyotypes
were significantly different in NPM1+/2 and NPM1+/+ patients.
In NPM1+/+ structural chromosome rearrangements (transloca-
tions; deletions; insertions; inversions) were significantly more
frequent (median 3, range 0–7 vs median 1.5, range 0–5;
P=0.013) (Table S2) but in the NPM1+/2 group gross
chromosomal changes (markers i.e. derivative chromosomes
unclassified by karyotyping, rings, and double minutes) were
significantly more common (median 3, range 0–9 vs median 0,
range 0–6; P,0.001) (Table S2). Aneuploidy was present in 47/64
NPM1+/+ patients (73%) and in 38/38 NPM1+/2 patients (100%)
(P,0.001). Significantly more monosomies were found in the
NPM1+/2 subgroup (median 2, range 0–8 vs median 1, range 0–6;
Figure1.FISH,cytogeneticsandmutationalanalysis. A) Resultsof FISHin 38patientswith MDS/AMLandNPM1monoallelicdeletion(NPM1+/2):
schema of 5q breakpoints. Upper: ideogram of the long arm of chromosome 5 in G banding. Lower: genomic clones at proximal (q11.2– q14.1 sub-
bands) and distal (q35.1–q35.3 sub-bands) breakpoints with percentages of cases. B) G-banded karyotype of a representative case (n.103,
Supporting Table S1) showed a complex karyotype including monosomies, unbalanced translocations, five markers, and a very small deleted
chromosome 5 corresponding to the largest 5q deletion including NPM1 with breakpoints at q11.2 and q35.3 (Right ideogram). C)F I S Ho fc a s e
n.103: concomitant deletion of RP11-117L6/NPM1 (green) and RP11-266N13 (red) indicate centromeric breakpoint (left) and RP1-240G13/
subtelomeric sequences (red) indicate telomeric breakpoint (right). Only one copy of each clone is present. D) Gene sequencing of case n.103 shows
no NPM1 exon 12 mutation in the non-deleted chromosome 5. The last 12 amino acids encoded by exon 12 of wild type NPM1 (NM_002520) are
annotated on top of the sequence.
doi:10.1371/journal.pone.0012855.g001
Figure 2. RT-qPCR and NPM1 gene expression. NPM1 expression
in 9 patients with MDS/AML NPM1+/2 (median: 0.5443; range:
0.1840.70), in 15 with MDS/AML NPM1+/+ (median: 0.96; range:
0.4443.20) and in 11 healthy controls (median 1.07; range
0.6141.50). Horizontal lines indicate median NPM1 expression in each
group. Y axis =2‘2DDCt value (NPM1 gene expression level normalized
to endogenous ABL1 gene) DCt=Ct NPM1 2Ct ABL1, DDCt= DCt sample2
DCtcalibrator. (P values according to the Mann-Whitney U test and
Bonferroni correction); n.s.= non significant.
doi:10.1371/journal.pone.0012855.g002
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detected in 18/38 (47%) of NPM1+/2 and in 11/64 (17%) of
NPM1+/+ (P=0.002).
Since NPM1 is related to TP53 [19,21223], a master gene of
chromosome stability that is frequently involved in MDS/AML
with complex karyotype [24], 57 cases from this series were
investigated (Table 3 and TableS1). Univariate analysis on TP53
and chromosome rearrangements showed a significant association
between the number of monosomies and TP53 deletion and/or
mutation (median 2 range 028 vs median 0 range 023; P=0.006)
(Table S3). However, both NPM1 and TP53 gene status
maintained significant association with monosomies in a multi-
variate analysis (P=0.014 and P=0.013, respectively) (Poisson
regression model), suggesting each gene plays an independent role,
but may interact synergistically, in determining chromosomal
abnormalities.
NPM1 loss was not associated with copy number variations of 14
genes other than TP53 that are putatively involved in the complex
regulatory network of genetic stability. Gains and losses of clones
containing BUB1A, ATR, FBW7, c-MYC, CDKN2A-2B, PTEN,
CHEK1, ATM, MDM2, BRCA2, RB1, BUB1B, BRCA, CHEK2 were
equally distributed in NPM1+/+ and NPM1+/2 cases (Figure 3),
suggesting that whatever roles these genes play in MDS/AML
Table 3. TP53 monoallelic deletion and/or mutations in 49/57
patients with MDS/AML and non-isolated 5q-.
TP53del TP53mut TP53del/TP53mut
NPM1+/+ 11 7 5
NPM1+/2 11 11 4
del, monoallelic deletion; mut, mutation.
doi:10.1371/journal.pone.0012855.t003
Figure 3. FISH investigations on clones encompassing 14 genes that are putatively involved in genomic stability. Gains (upper) and
losses (lower) in NPM1+/+ patients (white columns) and NPM1+/2 (grey columns).
doi:10.1371/journal.pone.0012855.g003
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deletion.
In conclusion these findings prove that haploinsufficiency of the
NPM1 gene, is present in more than 40% of patients with high risk
MDS/AML characterised by chromosome 5q- and complex
karyotypes. NPM1 haploinsufficiency and mutation appear to
exert very different effects (Figure 4) as patients with NPM1
mutated-AML have normal karyotype, rare TP53 involvement,
good prognosis if FLT3-ITD mutations are absent, and a
predominance of females [2,25,26]. NPM1 haploinsufficiency
was not linked to female gender (Table S4). It significantly
reduced NPM1 expression and, in synergy but independently of
TP53 deletion and/or mutation, was associated with a strong
tendency to perturb chromosomal stability. Consequently NPM1
gene status appears to indicate diverse genetic backgrounds in two
different myeloid leukemias.
Supporting Information
Table S1 Demographics, clinical findings, results of cytogenet-
ics, FISH and mutational analysis in 145 patients with MDS/
AML. Footnotes: M, male; F, female; RAEB, refractory anemia
with excess of blasts; RA, refractory anemia; AML, acute myeloid
leukemia; RCMD, refractory cytopenia with multilineage dyspla-
sia; MDS-U, myelodysplastic syndrome, unclassifiable; RARS,
refractory anemia with ringed sideroblasts; ex, exon; DEL,
monoallelic deletion; NL, normal hybridization pattern; GAIN,
$3 hybridization signals; (a) cases with NPM1 RT-qPCR analysis;
(b) copy number .5.
Found at: doi:10.1371/journal.pone.0012855.s001 (0.12 MB
XLS)
Table S2 Distribution of markers, monosomies, structural
aberrations, and trisomies in NPM1+/+ (0) and NPM1+/2 (1)
cases (Mann-Whitney U Test).
Found at: doi:10.1371/journal.pone.0012855.s002 (0.47 MB
DOC)
Table S3 Distribution of markers, monosomies, structural
aberrations, and trisomies according to the TP53 status (0= no
deletion or mutation; 1= deletion and/or mutation) (Mann-
Whitney U Test).
Found at: doi:10.1371/journal.pone.0012855.s003 (0.47 MB
DOC)
Table S4 Sex distribution between in NPM1+/+ and NPM1+/2
groups. Sex (males=0, females=1) distribution between in
NPM1+/+ (0) and NPM1+/2 (1) groups.
Found at: doi:10.1371/journal.pone.0012855.s004 (0.47 MB
DOC)
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